MDS Pharma Services Named Preferred CRO by MMRC

MDS Pharma Services has been selected as the preferred contract research organization (CRO) of the Multiple Myeloma Research Consortium (MMRC). MDS will manage multiple MMRC preclinical and clinical research efforts, including data management related to the MMRC’s tissue collection program. The MMRC will also recommend MDS to industry partners as additional protocols are brought through the Consortium.

“MDS Pharma Services is proud to have been chosen by the MMRC and we are ready to bring our global capabilities and oncology expertise to bear on the effort to fight multiple myeloma,” says Alan Morgan, vice president and general manager for Global Clinical Development.

“After I was diagnosed with myeloma, I worked with the scientific community to create the MMRC, which seeks to accelerate drug development and myeloma research by linking leading academic institutions through membership agreements, customized IT systems, and an integrated tissue bank,” says MMRC founder Kathy Giusti. “I’m pleased that MDS Pharma Services will be able to lend its global capability and oncology focus as the preferred CRO for the MMRC.”